Clinical trial NCT04247750: Testing SIROLIMUS in Beta-thalassemia Transfusion Dependent Patients (THALA-RAP)
Official title: Treatment of Beta-thalassemia Patients With Rapamycin (Sirolimus): From Pre-clinical Research to a Clinical Trial" - "Trattamento di Pazienti Con Beta-talassemia Con Rapamicina (Sirolimus): Dalla Ricerca Pre-clinica ad Uno Studio Clinico
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Beta-Thalassemia
Keywords: rapamycin
erythroid differentiation
γ-globin
fetal haemoglobin
Lead sponsor: Università degli Studi di Ferrara
Sponsor class: OTHER
Collaborators: name: Rare Partners srl Impresa Sociale
name: Meyer Children's Hospital IRCCS
name: Azienda Ospedaliero, Universitaria Pisana
First posted: 2020-01-30
Enrollment: 45
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Interventional, pilot, open-label phase II study with sirolimus in patients with transfusion-dependent beta-thalassemia
Primary purpose: TREATMENT

Brief summary: In β-thalassaemia and Sickle Cell Disease (SCD), a significant production of fetal haemoglobin (HbF) may reduce the severity of clinical course and reactivation of γ-globin gene expression in adulthood. HbF induction is one of the best strategies to ameliorate the characteristic symptoms of these diseases. Hydroxyurea (HU) is the only medication, approved by the US Food and Drug Administration, inducing HbF. However, treatments with HU induce sufficient HbF levels in only half of the patients, and side effects including leukopenia and neutropenia are frequently reported. Therefore, novel therapeutic inducers must be identified to develop a personalized treatment in β-thalassaemia and sickle cell anaemia. The availability of new treatments depends on drugs already approved for other indications, and on pharmacokinetics and pharmacovigilance already assessed. Rapamycin (as Sirolimus) is an immunosuppressant agent, approved by the FDA for acute rejection prevention in renal transplant recipients. The ability of this drug to induce γ-globin gene expression in erythroleukemia cell line and erythroid precursors cells (ErPCs) in ß-thalassaemia patients is already known. A clinical investigation on the effects of sirolimus in ß-Thalassaemia aims to evaluate several parameters related to red blood cell status and HbF levels and is a first step for the full clinical development in this new indication.

Detailed description: The general aim of this protocol is to demonstrate the applicability of a personalised and precision medicine approach in beta-thalassaemia; the clinical trial setting repurposes a drug, namely sirolimus. The presence of high Fetal Hemoglobin (HbF) levels is considered a condition predictive of a favourable outcome in thalassaemia. Its increase induced by pharmacological agents is considered a potential way to improve the clinical status of the patients. In terms of efficacy analysis, the investigators will focus their attention on HbF levels.

Primary objective:

• The suitability evaluation of sirolimus for the treatment of beta-thalassemia patients within the frame of a comprehensive project aimed at the reduction of their transfusions need, with consequent amelioration of their quality of life. The purpose can be achieved through increasing of HbF levels pharmacologically mediated, with verification of a prerequisite, namely the correlation between the induction of HbF in vitro and in vivo in single patients.

Secondary objectives:

* To assess the safety of sirolimus and correlation between administered dose and blood levels in beta-thalassemia patients
* To assess the influence of sirolimus on transfusion regimen
* To assess the effect of sirolimus on the hematopoietic and immune system of thalassemia patients.

Eligibility criteria: Inclusion Criteria:

* Patients over 18 years of age;
* Patients able to understand the informed consent and to sign it before any study procedure;
* Patients with β0/β0 and β+/β0 thalassaemia genotype;
* Documented diagnosis of major or intermediate thalassemia transfusion-dependent (number of transfusions not less than 8 over the past 12 months before selection);
* On regular transfusion since at least 6 years;
* Splenectomy performed at least 60 days before selection or spleen largest dimensions \< 20 cm as detected by abdominal echography;
* Female participants who are surgically sterilised/hysterectomised or post-menopausal for longer than 2 years or female participants of childbearing potential using and/or willing to continue using a medically reliable method of contraception for the entire study duration, such as oral, injectable, or implantable contraceptives, or intrauterine contraceptive devices, or using any other method considered sufficiently reliable by the investigator in individual cases. Patients must be counselled concerning measures to be used to prevent pregnancy and potential toxicities prior to the first dose of sirolimus;
* Patient willing to follow all the study requirements and perform all the study visits and to cooperate with the investigator;
* Patient followed by the same clinical site since at least 6 months.

Note that patients will be treated with oral sirolimus only in the case their Erythroid Precursor Cells (ErPCs) are responsive to the in vitro treatment with sirolimus according to laboratory-specific definition (≥ 20% increase of HbF in comparison with samples not treated with sirolimus);

Exclusion Criteria:

* Patient treated with hydroxyurea at selection visit or in the last 6 months;
* Ongoing treatment with drugs possibly affecting sirolimus actions;
* Documented aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \> 3x Upper Limit of Normal (ULN) at selection;
* Documented Platelet count \<150.000/microliter and \>1.000.000/microliter at selection;
* Heart failure as classified by the New York Heart Association (NYHA) classification 3 or higher;
* Uncontrolled hypertension defined as systolic blood pressure (BP) ≥ 140 mm Hg or diastolic BP ≥ 90 mm Hg;
* Significant arrhythmia requiring treatment,
* Corrected QT interval\> 450 msec on selection ECG;
* Ejection fraction \<50% by echocardiogram, multiple gated acquisition scan or cardiac magnetic resonance;
* Myocardial infarction within 6 months prior to selection;
* Positivity for human immunodeficiency virus (HIV) antibody, active hepatitis B (HBV) or hepatitis C (HCV) as demonstrated by the presence of hepatitis B surface antigen (HBsAg) and a positive HCV-RNA test, HBcAb and HBV-DNA positivity
* White blood cell \[WBC\] count \<3000 cells per μL and/or Granulocytes \<1500/mm3;
* Total cholesterol \> 240 mg/dl;
* Triglycerides \> 200 mg/dl;
* Proteinuria with urinary protein \>1g/24 hrs;
* Current participation in another trial with an investigational drug or experimental device, or inclusion in another trial with an investigational drug or experimental device within the preceding month;
* Major surgery (including splenectomy) within 60 days before selection (patients must have fully recovered from any previous surgery);
* Iron chelation therapy changed in the last 3 months prior to selection (note that Deferiprone is not accepted as a chelation therapy drug in this study while Desferrioxamine and Deferasirox are tolerated at stable dose);
* Current treatment with macrolide antibiotics (clarithromycin);
* Pregnant or lactating women;
* History of severe allergic or anaphylactic reactions or hypersensitivity to excipients in the experimental drug;
* Treatment with live vaccines within 90 days preceding the selection;
* Subject with history or current malignancies (solid tumours and haematological malignancies) or presence of masses/tumour detected by ultrasound at selection;
* Subject with any significant medical condition and/or laboratory abnormality considered by the investigator as not adequately controlled at the time of selection.

Primary outcomes:
measure: Change from baseline of fetal hemoglobin level
timeFrame: 360 days
Secondary outcomes:
measure: Change from baseline of fetal hemoglobin level
timeFrame: 90-180 days
measure: Change from baseline of γ-globin expression
timeFrame: 90-180-360 days
measure: Change from baseline of biomarkers for erythropoiesis
timeFrame: 180-360 days
measure: Change from baseline of biomarkers for erythropoiesis
timeFrame: 180-360 days
measure: Change from baseline of biomarkers for erythropoiesis
timeFrame: 180-360 days
measure: Change from baseline of biomarkers for erythropoiesis
timeFrame: 180-360 days
measure: Change from baseline of biomarkers for haemolysis
timeFrame: 180-360 days
measure: Change from baseline of biomarkers for haemolysis
timeFrame: 180-360 days
measure: Change from baseline of tranfusion needs
timeFrame: 360 days
measure: Change from baseline of tranfusion needs
timeFrame: 360 days
measure: Change from baseline of Iron status
timeFrame: 180-360 days
measure: Change from baseline of Iron status
timeFrame: 90-180-360 days
measure: Change from baseline of Immune function
timeFrame: 90-360 days
measure: Change from baseline of Immune function
timeFrame: 90-360 days
measure: Change from baseline of Quality of Life
timeFrame: 360 days
Other outcomes:
Locations:
city: Ferrara
country: Italy
facility: University of Ferrara Department of Life Sciences and Biotechnology
state: FE
city: Ferrara
country: Italy
facility: Day Hospital Thalassaemia and Haemoglobinopathies (DHTE) - Azienda Ospedaliero-Universitaria S.Anna of Ferrara
state: FE
city: Firenze
country: Italy
facility: Thalassemia and Hemoglobinopathies Center Azienda Ospedaliero Universitaria Meyer
state: Fi
city: Pisa
country: Italy
facility: Pediatric oncohematology Azienda Ospedaliero Universitaria Pisana Ospedale Santa Chiara
state: Pi
Study officials:
References: